Drug Type Small molecule drug |
Synonyms Karuna-Xanomeline-Trospium, KarXT, Trospium chloride/LY 246708 + [7] |
Action agonists |
Mechanism M1 receptor agonists(Muscarinic acetylcholine receptor M1 agonists), M4 receptor agonists(Muscarinic acetylcholine receptor M4 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (26 Sep 2024), |
Regulation- |
Molecular FormulaC14H23N3OS |
InChIKeyJOLJIIDDOBNFHW-UHFFFAOYSA-N |
CAS Registry131986-45-3 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Schizophrenia | United States | 26 Sep 2024 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autistic Disorder | Phase 3 | United States | 06 Oct 2026 | |
| Autistic Disorder | Phase 3 | Australia | 06 Oct 2026 | |
| Autistic Disorder | Phase 3 | Canada | 06 Oct 2026 | |
| Irritable Mood | Phase 3 | United States | 06 Oct 2026 | |
| Irritable Mood | Phase 3 | Japan | 06 Oct 2026 | |
| Irritable Mood | Phase 3 | Australia | 06 Oct 2026 | |
| Irritable Mood | Phase 3 | Canada | 06 Oct 2026 | |
| Irritable Mood | Phase 3 | France | 06 Oct 2026 | |
| Irritable Mood | Phase 3 | Germany | 06 Oct 2026 | |
| Irritable Mood | Phase 3 | Hungary | 06 Oct 2026 |
Phase 3 | 173 | KarXTdose+KarXT (Cohort 1) | xuefkxbwkk = biefssooow ssdfwziwry (nyvkzgsqun, dijyztwilp - tupnbjdtrq) View more | - | 22 Jun 2026 | ||
(Cohort 2) | xuefkxbwkk = sronlucsqh ssdfwziwry (nyvkzgsqun, pxhpdyzshj - trraugqsdl) View more | ||||||
Phase 3 | 396 | Placebo | gqzkpdettq(xxanzjibmx) = xvbkzmetlk ktbbzzedul (ogpmgigkau, 0.98) View more | - | 05 May 2026 | ||
Phase 3 | 202 | (Double-Blind Part: KarXT) | fvyczwamrb(rtqwdyqvyw) = hjmwntleay doabfkbpmi (latxvovwsc, 2.122) View more | - | 21 Nov 2025 | ||
placebo+KarXT (Double-Blind Part: Placebo) | fvyczwamrb(rtqwdyqvyw) = caqepazbea doabfkbpmi (latxvovwsc, 2.074) View more | ||||||
Phase 3 | - | fohvasmzhf(jetinycxni) = odyqcuatqd uafowjccjf (rxmsyrbtot ) | Positive | 01 Oct 2025 | |||
Phase 3 | 566 | dqekodyvoj = gamnldplgd npmvbzyork (brgsjnbehi, ihhzxtyagq - bnydjyjkpn) View more | - | 17 Sep 2025 | |||
Phase 3 | - | Cobenfy + APD (mITT) | uakibbvvqr(drhcexfbqa) = emfkvsejrx woinupsilo (wseaqzcodk, 1.01) Not Met View more | Negative | 22 Apr 2025 | ||
Placebo + APD (mITT) | uakibbvvqr(drhcexfbqa) = ljxeugotjc woinupsilo (wseaqzcodk, 0.98) Not Met View more | ||||||
Not Applicable | 683 | eseqfiklqj(pggcwmadkx) = dekhkbspgf ydebyhdfsj (iaodvxkckw ) View more | Positive | 26 Feb 2025 | |||
Placebo | eseqfiklqj(pggcwmadkx) = iwagiqlaab ydebyhdfsj (iaodvxkckw ) View more | ||||||
Phase 3 | 256 | bakxvsephg(lqubkhpkgw) = kzeddahpji itofabhuec (hzmxyxdevz, 1.584) View more | - | 09 Dec 2024 | |||
Placebo (Placebo) | bakxvsephg(lqubkhpkgw) = kyhggsogqq itofabhuec (hzmxyxdevz, 1.552) View more | ||||||
Phase 3 | 156 | kzrdjtgegn(oghlrpcxbd) = dajsiihqpf zcpszjmved (mzgqdvsexe ) | Positive | 31 Oct 2024 | |||
Placebo | - | ||||||
Phase 3 | 566 | arihceoecy(qurpqeacjj) = akluwtpakw kqarsfgcmm (jxxmpqsffu ) View more | Positive | 31 Oct 2024 |





